IMU 0.00% 3.4¢ imugene limited

2005 the year of imugene

  1. 4,996 Posts.
    • Pig pilot trial completed
    – Clinical trials fourth quarter 2004
    • Product development commenced for:
    – Poultry – E coli, Clostridia
    – Cattle - Clostridia
    – Pig rotavirus
    • Scale up to commercial production in TGA
    approved facility has commenced
    • Contract manufacturing and distribution via
    established international veterinary companies
    WHY CONTRACT MANUFACTURE? WHY CONTRACT MANUFACTURE?
    • Maximises shareholder returns
    – Lower capital expenditure
    – No time required for factory construction
    • TGA approved product sourced from approved
    contract manufacturer means regulatory process
    starts much earlier
    – Most rapid path to market
    – More sales during patent life
    • Flexibility in response to market demand
    ADENOVIRAL DELIVERY
    VECTOR TECHNOLOGY
    ADENOVIRAL DELIVERY
    VECTOR TECHNOLOGY
    Patented Platform Delivery System
    10 products currently under development
    – 7 vaccines against pig/poultry diseases
    – 3 biological productivity enhancers
    – Large international markets
    – Rapid development of new products for new
    diseases
    • PRRS (‘pig reproductive & respiratory disease”)
    • Avian Influenza (‘bird flu’)
    COMPETITIVE ADVANTAGES COMPETITIVE ADVANTAGES
    • Vaccines are highly protective
    • Easy to administer (feed, water or aerosol)
    • Trials increase poultry/pig growth up to 10%
    • Antibiotic feed additives deliver <4%
    • Vaccines are effective against some diseases that
    existing vaccines cannot protect against
    • Residue free in animal
    • No genetic modification of animal
    CURRENT AGREEMENTS CURRENT AGREEMENTS
    • Merial (Merck and Aventis) – world leading animal
    health company (annual turnover of US$1.7 b)
    – 3 vector products under contract
    • Market leader in Viral Vector Vaccines
    • External recognition
    • Merial to fund all regulatory, trial and scale up
    manufacturing costs
    • Expertise/resources in international product
    development, regulatory affairs and marketing
    LEAD PRODUCTS LEAD PRODUCTS
    2004 2005 2006 2007 2008
    Vaccines
    Immune
    E. coli
    Trials Regulatory Product Sales
    Market size = $450 m
    > $1,000 m
    > $1,000 m
    onwards
    RMT
    Enhancers
    MANAGEMENT TEAM MANAGEMENT TEAM
    • Strong management team
    – proven experience in international animal health
    companies
    – Taking products from research to international
    markets
    – Management of R&D under commercial
    guidelines
    – Integrating research and regulatory affairs
    STRATEGIC DIRECTION STRATEGIC DIRECTION
    Continue to increase shareholder value
    strong focus on commercialisation
    contract ‘bio-manufacturing’ & partnering
    arrangements
    lead products have large markets and near term
    market launches
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
3.4¢
Change
0.000(0.00%)
Mkt cap ! $150.4M
Open High Low Value Volume
3.6¢ 3.8¢ 3.4¢ $1.124M 31.49M

Buyers (Bids)

No. Vol. Price($)
21 4207221 3.3¢
 

Sellers (Offers)

Price($) Vol. No.
3.5¢ 2504069 8
View Market Depth
Last trade - 16.10pm 14/07/2020 (20 minute delay) ?
(live)
Last
3.5¢
  Change
0.000 ( 2.94 %)
Open High Low Volume
3.6¢ 3.8¢ 3.4¢ 17054248
Last updated 15.40pm 14/07/2020 (live) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.